John Caloz - LadRx Treasurer CFO
| LADXDelisted Stock | USD 2.37 0.14 6.28% |
Insider
John Caloz is Treasurer CFO of LadRx
| Age | 71 |
| Phone | 310 826 5648 |
| Web | https://www.cytrx.com |
LadRx Management Efficiency
The company has return on total asset (ROA) of (0.3427) % which means that it has lost $0.3427 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6365) %, meaning that it created substantial loss on money invested by shareholders. LadRx's management efficiency ratios could be used to measure how well LadRx manages its routine affairs as well as how well it operates its assets and liabilities.LadRx currently holds 322.33 K in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. LadRx has a current ratio of 1.79, which is within standard range for the sector. Debt can assist LadRx until it has trouble settling it off, either with new capital or with free cash flow. So, LadRx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like LadRx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for LadRx to invest in growth at high rates of return. When we think about LadRx's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| JeanMarc MBA | Iovance Biotherapeutics | 52 | |
| McKee MD | GeoVax Labs | 72 | |
| Paul MSc | Bavarian Nordic AS | 56 | |
| Sazzad MSc | InMed Pharmaceuticals | 66 | |
| JeanChristophe May | Bavarian Nordic AS | 56 | |
| Terrence MD | Arch Therapeutics | 58 | |
| David MBA | Seres Therapeutics | 63 | |
| Jeffrey MD | NovaBay Pharmaceuticals | 61 | |
| Esq JD | Iovance Biotherapeutics | 48 | |
| Jeffrey Welch | GeoVax Labs | N/A | |
| Jesse Shefferman | Protara Therapeutics | 52 | |
| Henrik MSc | Bavarian Nordic AS | 58 | |
| Robert MD | Lexicon Pharmaceuticals | 80 | |
| Audrey MD | NovaBay Pharmaceuticals | 65 | |
| Michael Abrams | Arch Therapeutics | 53 | |
| Mike Kelly | Lexicon Pharmaceuticals | N/A | |
| Yenyou Zheng | NovaBay Pharmaceuticals | 62 | |
| Kristine Rosse | Protara Therapeutics | N/A | |
| Swan Sit | NovaBay Pharmaceuticals | 41 | |
| Michael PEng | InMed Pharmaceuticals | 55 | |
Management Performance
| Return On Equity | -1.64 | ||||
| Return On Asset | -0.34 |
LadRx Leadership Team
Elected by the shareholders, the LadRx's board of directors comprises two types of representatives: LadRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LadRx. The board's role is to monitor LadRx's management team and ensure that shareholders' interests are well served. LadRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LadRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Caloz, Treasurer CFO | ||
| Terri Stevens, Chief Officer | ||
| Felix Kratz, Drug VP | ||
| Cristina Newman, Co Sec | ||
| Molly Poarch, Global Communications | ||
| Molly Painter, Pres Operations | ||
| Stephen Snowdy, Chief Officer |
LadRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is LadRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.64 | ||||
| Return On Asset | -0.34 | ||||
| Current Valuation | 7.5 M | ||||
| Shares Outstanding | 45.04 M | ||||
| Shares Owned By Insiders | 9.76 % | ||||
| Shares Owned By Institutions | 9.30 % | ||||
| Number Of Shares Shorted | 294.31 K | ||||
| Price To Book | 8.48 X | ||||
| Price To Sales | 34.48 X | ||||
| EBITDA | (5.97 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in unemployment. Note that the LadRx information on this page should be used as a complementary analysis to other LadRx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in LadRx OTC Stock
If you are still planning to invest in LadRx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LadRx's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |